Evidence map›Paper›PMID 21972247›Full record

ArticleMolecular & cellular proteomics : MCP2012

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) impairs the regulation of apoptosis in megakaryocytes by activating NF-κB: a proteomic study.

Michela Di Michele, Karen Peeters, Serena Loyen, Chantel Thys, Etienne Waelkens, Lutgart Overbergh, Marc Hoylaerts, Christel Van Geet, Kathleen Freson

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Protective Effects of PACAP in Peripheral Organs.Frontiers in endocrinology · 2020
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Michela Di MicheleCenter for Molecular and Vascular Biology, Leuven, Belgium.
Karen PeetersCenter for Molecular and Vascular Biology, Leuven, Belgium.
Serena LoyenCenter for Molecular and Vascular Biology, Leuven, Belgium.
Chantel ThysCenter for Molecular and Vascular Biology, Leuven, Belgium.
Etienne WaelkensLaboratory of Biochemistry, Leuven, Belgium.
Lutgart OverberghLaboratory for Experimental Medicine and Endocrinology, Leuven, Belgium.
Marc HoylaertsCenter for Molecular and Vascular Biology, Leuven, Belgium.
Christel Van GeetCenter for Molecular and Vascular Biology, Leuven, Belgium; Department of Pediatrics, University Hospital Leuven, K.U. Leuven, Leuven, Belgium.
Kathleen FresonCenter for Molecular and Vascular Biology, Leuven, Belgium. Electronic address: kathleen.freson@med.kuleuven.be.
VIB-KU Leuven Center for Cancer Biology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously showed that the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and its receptor VPAC1 are negative regulators of megakaryopoiesis and platelet function, but their downstream signaling pathway that inhibits this process still remained unknown. A combined proteomic, transcriptomic, and bioinformatic approach was here used to elucidate the molecular mechanisms underlying PACAP signaling via VPAC1 in megakaryocytes. Two-dimensional difference gel electrophoresis and tandem MS were applied to detect differentially expressed proteins in megakaryocytic CHRF cells stimulated with PACAP. The majority of the 120 proteins modulated by PACAP belong to the class of "cell cycle and apoptosis" proteins. The up- or down-regulated expression of some proteins was confirmed by immunoblot and immunohistochemical analysis. A meta-analysis of our data and 12 other published studies was performed to evaluate signaling pathways involved in different cellular models of PACAP response. From 2384 differentially expressed genes/proteins, 83 were modulated by PACAP in at least three independent studies and Ingenuity Pathway Analysis further identified apoptosis as the highest scored network with NF-κB as a key-player. PACAP inhibited serum depletion-induced apoptosis of CHRF cells via VPAC1 stimulation. In addition, PACAP switched on NF-κB dependent gene expression since higher nuclear levels of the active NF-κB p50/p65 heterodimer were found in CHRF cells treated with PACAP. Finally, a quantitative real time PCR apoptosis array was used to study RNA from in vitro differentiated megakaryocytes from a PACAP overexpressing patient, leading to the identification of 15 apoptotic genes with a 4-fold change in expression and Ingenuity Pathway Analysis again revealed NF-κB as the central player. In conclusion, our findings suggest that PACAP interferes with the regulation of apoptosis in megakaryocytes, probably via stimulation of the NF-κB pathway.

Indexed as

AdultApoptosisCell LineCyclic AMPGene ExpressionHumansLeukocytesMaleMegakaryocytesNF-kappa BPituitary Adenylate Cyclase-Activating PolypeptideProteomicsReverse Transcriptase Polymerase Chain ReactionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationCyclic AMPNF-kappa BPituitary Adenylate Cyclase-Activating Polypeptide

Identifiers

PMID21972247
PMCPMC3270095
OpenAlexW2169597486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.